Erratum: Expression of concern: DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine (PLoS ONE (2014) 9:1 (e84982) DOI: 10.1371/journal.pone.0084982);DUSP1 Is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Liu, Fang ^a   Gore, A Jesse ^a   Wilson, Julie L ^a   Korc, Murray ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; DOXYCYCLINE; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; STRESS ACTIVATED PROTEIN KINASE 1;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CARCINOGENICITY; CELL DEATH; CHEMOSENSITIVITY; COLONY FORMATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MITOGENESIS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; UPREGULATION; WNT SIGNALING PATHWAY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; DUAL SPECIFICITY PHOSPHATASE 1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896921230     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0233098     Document Type: Erratum

References (41)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer Statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362: 1605-1617.
3. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, et al. (1997) Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15: 2403-2413. (Pubitemid 27251144)
4. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, et al. (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol 29: 4548-4554.
5. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D, et al. (2011) Pancreatic cancer: Understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8: 27-33.
6. Chu GC, Kimmelman AC, Hezel AF, DePinho RA (2007) Stromal biology of pancreatic cancer. J Cell Biochem 101: 887-907. (Pubitemid 47040870)
7. Mahadevan D, Von Hoff DD (2007) Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6: 1186-1197. (Pubitemid 46711982)
8. Hung SW, Mody HR, Govindarajan R (2012) Overcoming nucleoside analog chemoresistance of pancreatic cancer: A therapeutic challenge. Cancer Lett 320: 138-149.
9. Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549.
10. Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947. (Pubitemid 39626217)
11. Bermudez O, Pages G, Gimond C (2010) The dual-specificity MAP kinase phosphatases: Critical roles in development and cancer. Am J Physiol Cell Physiol 299: 189-202.
12. Liu YX, Wang J, Guo J, Wu J, Lieberman HB, Yin Y (2008) DUSP1 is controlled by p53 during the cellular response to oxidative stress. Mol Cancer Res 6: 624-633. (Pubitemid 351521844)
13. Wang J, Yin DP, Liu YX, Baer R, Yin Y (2007) Dual specificity phosphatase 1/ CL100 is a direct transcriptional target of E2F-1 in the apoptotic response to oxidative stress. Cancer Res 67: 6737-6744. (Pubitemid 47105520)
14. Laderoute KR, Mendonca HL, Calaoagan JM, Knapp AM, Giaccia AJ, Stork PJ (1999) Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun N-terminal protein kinase activity. J Biol Chem 274: 12890-12897.
15. Liao Q, Guo J, Kleeff J, Zimmermann A, Buchler MW, et al. (2003) Downregulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology 124: 1830-1845. (Pubitemid 36666779)
16. Vicent S, Garayoa M, López-Picazo JM, Lozano MD, Toledo G, et al. (2004) Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res 10: 3639-3649. (Pubitemid 38697597)
17. Wang HY, Cheng Z, Malbon CC (2003) Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 191: 229-237. (Pubitemid 36255609)
18. Denkert C, Schmitt WD, Berger S, Reles A, Pest S, et al. (2002) Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int J Cancer 102: 507-513. (Pubitemid 35316006)
19. Bang YJ, Kwon JH, Kang SH, Kim JW, Yang YC. (1998) Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma. Biochem Biophys Res Commun 250: 43-47. (Pubitemid 28448619)
20. Loda M, Capodieci P, Mishra R, Yao H, Corless C, et al. (1996) Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol 149: 1553-1564. (Pubitemid 26363962)
21. Wang J, Zhou JY, Zhang L, Wu GS (2009) Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cell Cycle 8: 3191-3198.
22. Small GW, Shi YY, Higgins LS, Orlowski RZ (2007) Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 67: 4459-4466. (Pubitemid 46815096)
23. Srikanth S, Franklin CC, Duke RC, Kraft RS (1999) Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Mol Cell Biochem 199: 169-178. (Pubitemid 29476155)
24. Calvisi DF, Pinna F, Meloni F, Ladu S, Pellegrino R, et al. (2008) Dualspecificity phosphatase 1 ubiquitination in extracellular signal-regulated kinasemediated control of growth in human hepatocellular carcinoma. Cancer Res 68: 4192-4200.
25. Casals-Casas C, Alvarez E, Serra M, de la Torre C, Farrera C, et al. (2009) CREB and AP-1 activation regulates MKP-1 induction by LPS or M-CSF and their kinetics correlate with macrophage activation versus proliferation. Eur J Immunol 39: 1902-1913.
26. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, et al. (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: 3946-3952. (Pubitemid 46630743)
27. Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, et al. (2010) Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 101: 587-592.
28. Fryer RA, Barlett B, Galustian C, Dalgleish AG (2011) Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiDTM lenalidomide. Anticancer Res 31: 3747-3756.
29. Moncho-Amor V, Ibanez de Cáceres I, Bandres E, Martínez-Poveda B, Orgaz JL, et al. (2011) DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer. Oncogene 30: 668-678.
30. Korc M (2003) Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2: 1-8.
31. Comalada M, Lloberas J, Celada A. (2012) MKP-1: A critical phosphatase in the biology of macrophages controlling the switch between proliferation and activation. Eur J Immunol 42: 1938-1948.
32. Kschutte M., Hruban R.H., Geradts J., Maynard R., Hilgers W., et al. (1997) Abrogation of the Rb/p16 Tumor-suppressive Pathway in Virtually All Pancreatic Carcinomas. Cancer Res 57: 3126-3130. (Pubitemid 27351723)
33. Schild C, Wirth M, Reichert M, Schmid RM, Saur D, Schneider G (2009) PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells. Mol Carcinog 48: 1149-1158.
34. Morgan RT, Woods LK, Moore GE, Quinn LA, McGavran L, et al. (1980) Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma. Int J Cancer 25: 591-598. (Pubitemid 10156843)
35. Kleeff J, Korc M (1998) Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-beta1 in COLO-357 cells. J Biol Chem 273: 7495-7500. (Pubitemid 28152773)
36. Arnold NB, Arkus N, Gunn J, Korc M (2007) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 13: 18-26. (Pubitemid 46121848)
37. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, et al. (2005) Chromosomewide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122: 33-43. (Pubitemid 40977938)
38. Liu F, Korc M (2012) Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther 11: 2138-2148.
39. Gu D, Liu H, Su GH, Zhang X, Chin-Sinex H, et al. (2013) Combining hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis. Mol Cancer Ther 12: 1038-1048.
40. Chang SC, Brannon PM, Korc M (1990) Effects of dietary manganese deficiency on rat pancreatic amylase mRNA levels. J Nutr 120: 1228-1234. (Pubitemid 20359978)
41. Carriere C, Gore AJ, Norris AM, Gunn JR, Young AL, et al. (2011) Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions. Gastroenterology 141: 1091-1101.